分类: 核科学技术 >> 核材料与工艺技术 提交时间: 2023-06-18 合作期刊: 《Nuclear Science and Techniques》
摘要: This study was to evaluate effect of 125I brachytherapy combined with chemotherapy on advanced non-small cell lung cancer (NSCLC). Patients with NSCLC in stages III to IV were divided into two groups: Group A (n=27) received 125I brachytherapy combined with gemcitabine and cisplatin (GP) chemotherapy, and Group B (n=27) received GP chemotherapy only. The results showed that the overall response rate and median progression-free survival time were 78% and 11.5 months in Group A, 41% and 8 months in Group B, respectively (PP>0.05). The interventional complications in Group A included 5 patients with postoperative pneumothorax and 4 patients with hemoptysis. No patients had radiation pneumonia, radiation esophagitis or esophagotracheal fistula. Chemotherapy treatment-related toxicities were not significantly different between the two groups. The relief of tumor-associated symptoms including cough, hemoptysis, chest pain, and short breath was found in both groups, without statistical difference in remission rates between Groups A and B (P>0.05). In conclusion, 125I brachytherapy combined with chemotherapy proved to be safe and effective for treating advanced NSCLC with few complications. It improves local control rate and prolongs the progression-free survival time.
分类: 核科学技术 >> 核材料与工艺技术 提交时间: 2023-06-18 合作期刊: 《Nuclear Science and Techniques》
摘要: In this paper, the safety and efficacy of 131I-labeled mouse/human chimeric monoclonal antibody (131I-chTNT)-mediated radioimmunotherapy are evaluated because the patients have non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma (DTC). The 16 patients were injected intravenously by 29.63.7 MBqkg1 using 131I-chTNT. The chest computer tomography was performed before treatment, as well as 28 and 70 days after treatment. Responses and safety were assessed during the treatment. The results show that the 131I-chTNT infusion was well tolerated with the 12.5% complete response, 18.8% partial response, 25.0% progressive disease, and the 43.8% stable disease, indicating that most treatment-related adverse effects are mild transient and reversible. The 131I-chTNT is promising for patients with non-uptaking the 131I pulmonary metastases from DTC.